Lisata Therapeutics (LSTA) Institutional Ownership → Biden to Drop BOMBSHELL June 13th? (From Paradigm Press) (Ad) Free LSTA Stock Alerts $2.84 -0.12 (-4.05%) (As of 05/15/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Lisata Therapeutics (NASDAQ:LSTA)CurrentInstitutional OwnershipPercentage8.94%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$117.25KNumber ofInstitutional Sellers(last 12 months)0 Get LSTA Insider Trade Alerts Want to know when executives and insiders are buying or selling Lisata Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LSTA Institutional Buying and Selling by Quarter Ad Manward PressAmazon's betting big on this unknown AI companyAmazon's Betting Big on This Unknown AI Company Amazon has just made a stunning $144 million investment in one small AI company.Discover why this company Lisata Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails4/23/2024 BML Capital Management LLC284,669$888K0.6%+5.5%3.426% 1/30/2024 BML Capital Management LLC269,839$737K0.6%+10.7%3.315% 2/13/2023 BML Capital Management LLC243,839$617K0.6%N/A3.102% (Data available from 1/1/2016 forward) LSTA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LSTA shares? During the previous two years, the following institutional investors and hedge funds held shares of Lisata Therapeutics shares: BML Capital Management LLC ($888K).Learn more on LSTA's institutional investors. What percentage of Lisata Therapeutics stock is owned by institutional investors? 8.94% of Lisata Therapeutics stock is owned by institutional investors. Learn more on LSTA's institutional investor holdings. Which institutional investors have been buying Lisata Therapeutics stock? The following institutional investors have purchased Lisata Therapeutics stock in the last 24 months: BML Capital Management LLC ($284.67K). How much institutional buying is happening at Lisata Therapeutics? Institutional investors have bought a total of 284,669 shares in the last 24 months. This purchase volume represents approximately $734.16K in transactions. Related Companies: RenovoRx Institutional Ownership Forte Biosciences Institutional Ownership Iterum Therapeutics Institutional Ownership Oncternal Therapeutics Institutional Ownership TherapeuticsMD Institutional Ownership Unity Biotechnology Institutional Ownership Bullfrog AI Institutional Ownership Biora Therapeutics Institutional Ownership Cumberland Pharmaceuticals Institutional Ownership Benitec Biopharma Institutional Ownership This page (NASDAQ:LSTA) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsTop 5 AI Stocks to Buy for 2024Market Moving TrendsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 Tech Stocks to Buy for 2024Daily Market AlertsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
